TD Asset Management Inc Boosts Position in GeneDx Holdings Corp. $WGS

Key Points

• TD Asset Management Inc increased its holdings in GeneDx Holdings Corp. by 108.0% during Q2, now owning approximately 0.12% of the company valued at $3.25 million.
• Analyst ratings for GeneDx have varied, with Piper Sandler raising its price target to $140.00 and Zacks downgrading it to a "hold" rating, indicating a consensus of "Moderate Buy" with an average price target of $109.78.
• Insider transactions included CEO Katherine Stueland selling over 10,500 shares and CFO Kevin Feeley selling approximately 3,728 shares, significantly reducing their ownership stakes.

TD Asset Management Inc boosted its position in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 108.0% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 35,258 shares of the company's stock after purchasing an additional 18,310 shares during the quarter. TD Asset Management Inc owned approximately 0.12% of GeneDx worth $3,255,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC boosted its position in GeneDx by 151.7% during the first quarter. GAMMA Investing LLC now owns 438 shares of the company's stock worth $39,000 after purchasing an additional 264 shares in the last quarter. US Bancorp DE boosted its position in GeneDx by 3,223.5% during the first quarter. US Bancorp DE now owns 565 shares of the company's stock worth $50,000 after purchasing an additional 548 shares in the last quarter. KBC Group NV purchased a new stake in shares of GeneDx in the first quarter valued at $81,000. PNC Financial Services Group Inc. purchased a new stake in shares of GeneDx in the first quarter valued at $132,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of GeneDx by 184.8% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,224 shares of the company's stock valued at $197,000 after acquiring an additional 1,443 shares in the last quarter. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on WGS shares. Piper Sandler upped their price objective on GeneDx from $120.00 to $140.00 and gave the company an "overweight" rating in a research report on Thursday, September 11th. Wells Fargo & Company upped their price objective on GeneDx from $78.00 to $95.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 30th. Wall Street Zen upgraded GeneDx from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Weiss Ratings restated a "sell (d)" rating on shares of GeneDx in a research report on Wednesday, October 8th. Finally, Zacks Research downgraded GeneDx from a "strong-buy" rating to a "hold" rating in a research report on Thursday, October 2nd. Seven analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, GeneDx currently has a consensus rating of "Moderate Buy" and an average target price of $109.78.

GeneDx Stock Performance

NASDAQ WGS opened at $127.03 on Tuesday. The business's 50-day moving average price is $123.07 and its 200 day moving average price is $96.73. GeneDx Holdings Corp. has a twelve month low of $55.17 and a twelve month high of $136.00. The company has a market capitalization of $3.65 billion, a PE ratio of 2,540.60 and a beta of 1.98. The company has a current ratio of 2.87, a quick ratio of 2.70 and a debt-to-equity ratio of 0.19.

GeneDx (NASDAQ:WGS - Get Free Report) last released its earnings results on Tuesday, July 29th. The company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.40. GeneDx had a return on equity of 16.51% and a net margin of 0.39%.The firm had revenue of $102.69 million for the quarter, compared to the consensus estimate of $86.00 million. GeneDx has set its FY 2025 guidance at EPS. On average, research analysts predict that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Insider Transactions at GeneDx

In other news, CEO Katherine Stueland sold 10,501 shares of the firm's stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $121.47, for a total value of $1,275,556.47. Following the transaction, the chief executive officer directly owned 14,578 shares in the company, valued at $1,770,789.66. This trade represents a 41.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Kevin Feeley sold 3,728 shares of the firm's stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $121.47, for a total value of $452,840.16. Following the completion of the transaction, the chief financial officer owned 8,755 shares in the company, valued at approximately $1,063,469.85. This trade represents a 29.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 556,371 shares of company stock valued at $67,489,314. 29.60% of the stock is owned by company insiders.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.